A recent CBS News article noted an important milestone in the fight against Alzheimer’s: the first blood test to diagnose it has hit the market. The test was developed by C2N Diagnostics in St. Louis, and the founders are doctors from Washington University School of Medicine. It costs $1,250 and produces results in about 10 days, but the company offers discounts based on income. While the test aims to provide patients with easier diagnoses, the facts that key test results have yet to be published, and the test isn’t FDA approved raise accuracy concerns.
First Alzheimer’s Test Hit Market Sans FDA Approval
The new blood test costs about 75% less than current brain scans.
Dec 2, 2020
Recommended
Recommended
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
